Loading organizations...
Venock has raised $600K across 2 funding rounds.
Key people at Venock.
Venock has raised $600K in total across 2 funding rounds.
Venock Inc. develops advanced vascular closure devices for large bore access sites during interventional transcatheter therapies. Its core product targets venous and arterial perforations exceeding 8mm, providing rapid hemostasis. This proprietary technology achieves complete closure within one minute, significantly improving upon slow, discomforting manual compression methods and reducing overall procedure time.
Led by CEO Terry Barnes, Venock operates from its New York City headquarters with additional operations in Munich, Germany. The company originated from the critical insight that existing large bore vascular access closure methods are inefficient and burdensome for both clinicians and patients. This understanding drove the development of an automated device to expedite post-procedural care and enhance the patient experience.
Venock’s device serves patients undergoing complex cardiovascular interventions requiring substantial vascular access. The company envisions its technology becoming the definitive standard for swift and effective vascular closure, optimizing procedural workflows and accelerating patient recovery. Venock is committed to broadening its applications to address diverse large bore access needs universally.
Venock has raised $600K across 2 funding rounds. Most recently, it raised $500K Seed in February 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2019 | $500K Seed | — | NEW AGE Ventures | Announced |
| Nov 1, 2018 | $100K Seed | — | NEW AGE Ventures | Announced |
Key people at Venock.
Venock has raised $600K in total across 2 funding rounds.
Venock's investors include New Age Ventures.
Venock Inc. is a US-based medical device company specializing in the development of a novel vascular closure device designed to close large bore venous access sites (>8 mm) rapidly after transcatheter therapies. Their product targets patients undergoing interventional procedures requiring large venous access, offering a solution that significantly reduces procedure time, patient discomfort, and healthcare costs by enabling closure in under one minute. This innovation improves cathlab efficiency by increasing patient turnover and allowing quicker ambulation and discharge, addressing a critical bottleneck in cardiovascular interventions[2][5].
Founded in September 2018, Venock was established by a team combining deep expertise in cardiovascular device engineering, clinical cardiology, and business operations. Key founders include Terry, a medical device executive with over 20 years in cardiovascular device design; Wolfgang, a cardiac surgeon and interventional cardiologist with clinical and research experience; and Marcus, a serial entrepreneur with a background in business administration. The idea emerged from the clinical need to improve closure of large bore venous punctures, which were traditionally time-consuming and painful for patients. Early traction includes prototype readiness and recognition such as the 2023 CSI Innovation Award, validating their approach and technology[2][5].
Venock is positioned at the intersection of growing demand for minimally invasive cardiovascular interventions and the need for procedural efficiency in cathlabs worldwide. The trend toward transcatheter therapies requiring large bore venous access is expanding, increasing the urgency for effective closure solutions. Venock’s device addresses market forces such as rising healthcare costs, patient-centric care models emphasizing faster recovery, and limited cathlab resources. By innovating in vascular closure technology, Venock influences the broader MedTech ecosystem by enabling more scalable, patient-friendly interventional cardiology procedures[4][5].
Venock’s next phase likely involves advancing regulatory approvals, scaling manufacturing, and expanding clinical adoption globally. Trends shaping their journey include the continued growth of transcatheter therapies and increasing demand for devices that improve procedural efficiency and patient outcomes. As Venock’s technology gains traction, it may set new standards for venous closure, potentially expanding into arterial closure or other vascular applications. Their influence could extend beyond device innovation to shaping cathlab workflow optimization and patient care protocols, reinforcing their role as a key player in cardiovascular MedTech innovation[5].
